Key result
This review discusses the impact of dual antiplatelet therapy on bleeding complications, transfusion requirements, and perioperative management in patients undergoing cardiac surgery.
Why the study?
How does perioperative platelet inhibition affect bleeding complications and transfusion requirements in cardiac surgery patients?
How does perioperative platelet inhibition affect bleeding complications and transfusion requirements in cardiac surgery patients?
This review discusses the perioperative management of antiplatelet therapy in cardiac surgery patients to balance thrombotic risks and bleeding complications.
Cautious perioperative DAPT decisions may be informed in cardiac surgery; leaves optimal strategies open for prospective trials.
Dual antiplatelet therapy (DAPT) with acetylsalicylic acid and a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) reduces thrombotic events in patients with acute coronary syndrome (ACS), but it is also associated with an increased risk of bleeding complications. Excessive bleeding in cardiac surgery patients is associated with increased morbidity and mortality and high costs. In this review, different aspects of platelet inhibition in cardiac surgery patients will be discussed, including direct effects on bleeding and transfusion requirements, discontinuation and reinstitution of antiplatelet drugs before and after surgery, and the use of perioperative platelet function testing.
No takes yet. Share an insight, caveat, or question.
Hansson et al. (2016) conducted a review in Cardiac surgery. Dual antiplatelet therapy (DAPT) was evaluated. This review discusses the impact of dual antiplatelet therapy on bleeding complications, transfusion requirements, and perioperative management in patients undergoing cardiac surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: